Voting on resolutions to regulate the cultivation and registration of cannabis-primarily based medicines in Brazil has been postponed, the Agência Nacional de Vigilância Sanitária – or National Sanitary Surveillance Agency (ANVISA) – announced Monday.
Voting was initially scheduled to take location Tuesday. The delay throws the future of the groundbreaking proposals in doubt.
The explanation provided for the postponement was that directors of the agency produced ideas to modify the original text of the resolutions. This suggests the other directors and technical teams have to have time to evaluate these adjustments.
The proposed adjustments and the identities of who recommended them have been not disclosed.
The situation will now be taken up at ANVISA’s subsequent meeting, scheduled for Oct. 15.
Approval demands a very simple majority of the agency’s five directors.
ANVISA’s proposals generated intense opposition from specific sectors of the government.
Nearby market sources who spoke with Marijuana Organization Every day worry that voting could be additional postponed.
If the vote is not carried out prior to December, the probabilities of approval would drastically reduce since new members of the directory, appointed by President Jair Bolsonaro, would substitute existing members, who are in favor of the proposals, like ANVISA Director-President William Dib.
By December, Bolsonaro will have appointed 3 of the 5 members of the Collegiate Board of Directors.
Presently, Brazil is the biggest Latin American health-related cannabis industry, regardless of getting a restrictive, import-only framework.
Far more than 10,000 authorizations have been granted considering the fact that the starting of the system in 2014, and there are at the moment about five,000 active individuals.